Israeli biotechnology company Pluristem Therapeutics has announced that its subsidiary, Pluristem Ltd. has signed a memorandum of understanding with the Abu Dhabi Stem Cells Center (ADSCC), which is working on a stem cell-based treatment for coronavirus.
The ADSCC was founded in 2019 to provide a solution to local and regional demand for special medical treatments. The center owns and operates advanced equipment and hosts an international renowned team of physicians who work on projects in the fields that include immunology, stem cells, molecular biology, immunotherapy, and urology.
Follow Israel Hayom on Facebook and Twitter
The two organizations will cooperate on developing drugs to treat serious diseases, including coronavirus.
The signing took place on video chat.
Pluristem President and CEO Yaky Yanay said, "We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that we believe will advance healthcare within and across our borders. We see life science and regenerative medicine as a bridge for building peace, prosperity, and well-being in our region and for the entire world. I believe it is our obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education. We are honored to be on the front line of this historical moment."
"Pluristem is a major player in the cell therapy field with years of experience, a unique platform and a robust clinical pipeline. We are excited to join forces and to promote the research and development of cell therapies for the best of the patients and the human society as a whole," said Dr. Yendry Ventura, a manager at the ADSCC.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
